Health
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
WILMINGTON, Del., October 17, 2025--Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG treatment alone.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/58ce082d68c57c7de4e19cefee5d646d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NbyCk3qbgWZgth.IoQ9PXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/58ce082d68c57c7de4e19cefee5d646d","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/p5M5DA1ttIKpiSiyHnnJLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/58ce082d68c57c7de4e19cefee5d646d","width":1181,"height":286}},"lazy":false},{"type":"text","content":"Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone","length":181,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., October 17, 2025--(BUSINESS WIRE)--Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG treatment alone.","length":445,"tagName":"p"},{"type":"text","content":"The results of this final analysis will be presented today during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (abstract #LBA108) and simultaneously published in The Lancet.","length":253,"tagName":"p"},{"type":"text","content":"With a median follow-up of more than five years (60.7 months), the IMFINZI regimen showed a 32% reduction in the risk of high-risk disease recurrence or death versus the comparator arm (based on a DFS hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.50-0.93; P=0.0154). Estimated median DFS was not yet reached for either arm. An estimated 87% of patients treated with the IMFINZI regimen remained alive and disease-free at two years compared to 82% in the comparator arm.","length":481,"tagName":"p"},{"type":"text","content":"The trial was not statistical...